Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals, Inc. company information, Employees & Contact Information

Explore related pages

Milestone Pharmaceuticals, Inc. email format Milestone Pharmaceuticals, Inc. management contacts

Related company profiles:

Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page. https://milestonepharmaceuticals.applytojob.com/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.

Company Details

Employees
68
Founded
-
Address
1111 Dr. Frederik-Philips, Montreal,qc H4m 2x6,canada
Phone
(514) 336-0444
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
milestonepharma.com
HQ
Montreal, QC
Competitors
Thryv Therapeutics Inc., EVERSANA, Alnylam Pharmaceuticals, Precigen, Citius Pharmaceuticals, Inc., Capricor Therapeutics, Inc., Arrowhead Pharmaceuticals, Crinetics Pharmaceuticals, Corcept Therapeutics, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT).
Looking for a particular Milestone Pharmaceuticals, Inc. employee's phone or email?

Milestone Pharmaceuticals, Inc. Questions

News

Game-Changing Heart Treatment Could Hit Market in 2025: Inside Milestone's Launch Strategy - Stock Titan

Game-Changing Heart Treatment Could Hit Market in 2025: Inside Milestone's Launch Strategy Stock Titan

Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update - PR Newswire

Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update PR Newswire

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301) - American Heart Association Journals

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301) American Heart Association Journals

Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm - JACC Journals

Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm JACC Journals

Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT - PR Newswire

Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT PR Newswire

Milestone's CARDAMYST Gets FDA Path Forward: Manufacturing Issues Only, $56M Cash Runway Revealed - Stock Titan

Milestone's CARDAMYST Gets FDA Path Forward: Manufacturing Issues Only, $56M Cash Runway Revealed Stock Titan

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 - PR Newswire

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 PR Newswire

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China - PR Newswire

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China PR Newswire

Companies like Milestone Pharmaceuticals, Inc.

Corcept Therapeutics logo - Similar company to Milestone Pharmaceuticals, Inc.

Corcept Therapeutics

634
Crinetics Pharmaceuticals logo - Similar company to Milestone Pharmaceuticals, Inc.

Crinetics Pharmaceut...

510
Arrowhead Pharmaceuticals logo - Similar company to Milestone Pharmaceuticals, Inc.

Arrowhead Pharmaceut...

625
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) logo - Similar company to Milestone Pharmaceuticals, Inc.

Arcutis Biotherapeut...

378
Citius Pharmaceuticals, Inc. logo - Similar company to Milestone Pharmaceuticals, Inc.

Citius Pharmaceutica...

20
Alnylam Pharmaceuticals logo - Similar company to Milestone Pharmaceuticals, Inc.

Alnylam Pharmaceuticals

2.58K
Capricor Therapeutics, Inc. logo - Similar company to Milestone Pharmaceuticals, Inc.

Capricor Therapeutic...

197
Thryv Therapeutics Inc. logo - Similar company to Milestone Pharmaceuticals, Inc.

Thryv Therapeutics Inc.

27
EVERSANA logo - Similar company to Milestone Pharmaceuticals, Inc.

Eversana

4.68K
Precigen logo - Similar company to Milestone Pharmaceuticals, Inc.

Precigen

131

Top Milestone Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant